Infect Chemother.  2009 Oct;41(5):265-271. 10.3947/ic.2009.41.5.265.

Treatment of Severe Pandemic Influenza A/H1N1 Infection

• Kim SH

• KMID: 1473651
• DOI: http://doi.org/10.3947/ic.2009.41.5.265

Abstract

No abstract available.

MeSH Terms

Influenza, Human
Pandemics

Reference

1. Dwyer D. Mini-lecture In Slide session on Novel H1N1 influenza: late-breakers. Program and absctracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2009. San Francisco, CA. American Society for Microbiology.

2. Swine flu-UK planning assumptions. Department of Health, UK. cited 2009 Oct 21. Available from: URL: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_104844.

3. Zilberberg MD, Sandrock C, Shorr A. Swine origin influenza A (H1N1) virus and ICU capacity in the US: Are we prepated? PLoS Currents Influenza. 2009. 22:RRN1009.

4. Sweet M. Pandemic lessons from Australia. Brit Med J. 2009. 339:b3317.

5. Flahault A. First estimation of direct H1N1pdm virulence: From reported non consolidated data from Mauritius and New Caledonia. PLoS Currents Influenza. 2009. RRN1010.

6. Rello J, Rodríguez A, Ibañez P, Socias L, Cebrian J, Marques A, Guerrero J, Ruiz-Santana S, Marquez E, Del Nogal-Saez F, Alvarez-Lerma F, Martnez S, Ferrer M, Avellanas M, Granada R, Maraví-Poma E, Albert P, Sierra R, Vidaur L, Ortiz P, Prieto Del, Galván B, León-Gil C. the H1N1 SEMICYUC working group. Intensive care adult patients with severe respiratory failure caused by Influenza A (H1N1)v in Spain. Crit Care. 2009. 13:R148. (Epub ahead of print on Sep 11 2009).

7. Vaillant L, La Ruche G, Tarantola A, Barboza P. epidemic intelligence team at InVS. Epidemiology of fatal cases associated with pandemic H1N1 influenza 2009. Euro Surveill. 2009. 14:pii:19309.

8. Wilson N, Baker MG. The emerging influenza pandemic: estimating the case fatality ratio. Euro Surveill. 2009. 14:pii:19255.

9. Miller MA, Viboud C, Balinska M, Simonsen L. The signature features of influenza pandemics-implications for policy. N Engl J Med. 2009. 360:2595–2598.

10. Nishiura H, Klinkenberg D, Roberts M, Heesterbeek JA. Early epidemiological assessment of the virulence of emerging infectious diseases: a case study of an influenza pandemic. PLoS One. 2009. 4:e6852.

11. Ruiz-Palacios GM. Ground zero: the emgergence of a pandemic? In Symphosium on Influenza: experiencing the unexpected. Program and absctracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2009. San Francisco, CA. American Society for Microbiology.

12. Hancock K, Veguilla V, Lu X, Zhong W, Butler EN, Sun H, Liu F, Dong L, Devos JR, Gargiullo PM, Brammer TL, Cox NJ, Tumpey TM, Katz JM. Cross-Reactive Antibody Responses to the 2009 Pandemic H1N1 Influenza Virus. N Engl J Med. 2009. (Epub ahead of print on Sept 10 2009).

13. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, Hatta M, Muramoto Y, Tamura D, Sakai-Tagawa Y, Noda T, Sakabe S, Imai M, Hatta Y, Watanabe S, Li C, Yamada S, Fujii K, Murakami S, Imai H, Kakugawa S, Ito M, Takano R, Iwatsuki-Horimoto K, Shimojima M, Horimoto T, Goto H, Takahashi K, Makino A, Ishigaki H, Nakayama M, Okamatsu M, Takahashi K, Warshauer D, Shult PA, Saito R, Suzuki H, Furuta Y, Yamashita M, Mitamura K, Nakano K, Nakamura M, Brockman-Schneider R, Mitamura H, Yamazaki M, Sugaya N, Suresh M, Ozawa M, Neumann G, Gern J, Kida H, Ogasawara K, Kawaoka Y. In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature. 2009. 460:1021–1025.

14. Neumann G, Noda T, Kawaoka Y. Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature. 2009. 459:931–939.

15. Tumpey TM, Basler CF, Aguilar PV, Zeng H, Solórzano A, Swayne DE, Cox NJ, Katz JM, Taubenberger JK, Palese P, García-Sastre A. Characterization of the reconstructed 1918 Spanish influenza pandemic virus. Science. 2005. 310:77–80.

16. Mcculiers JA. Influenza and bacteria: a lethal syngergism? In Symphosium on Influenza: experiencing the unexpected. Program and absctracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2009. San Francisco, CA. American Society for Microbiology.

17. Morens DM, Taubenberger JK. Understanding influenza backward. JAMA. 2009. 302:679–680.

18. Maines TR, Jayaraman A, Belser JA, Wadford DA, Pappas C, Zeng H, Gustin KM, Pearce MB, Viswanathan K, Shriver ZH, Raman R, Cox NJ, Sasisekharan R, Katz JM, Tumpey TM. Transmission and pathogenesis of swine-origin 2009 A(H1N1) influenza viruses in ferrets and mice. Science. 2009. 325:484–487.

19. Munster VJ, de Wit E, van den Brand JM, Herfst S, Schrauwen EJ, Bestebroer TM, van de Vijver D, Boucher CA, Koopmans M, Rimmelzwaan GF, Kuiken T, Osterhaus AD, Fouchier RA. Pathogenesis and transmission of swine-origin 2009 A(H1N1) influenza virus in ferrets. Science. 2009. 325:481–483.

20. Perez-Padilla R, de la Rosa-Zamboni D, Ponce de Leon S, Hernandez M, Quiñones-Falconi F, Bautista E, Ramirez-Venegas A, Rojas-Serrano J, Ormsby CE, Corrales A, Higuera A, Mondragon E, Cordova-Villalobos JA. INER Working Group on Influenza. Pneumonia and respiratory failure from swine-origin influenza A (H1N1) in Mexico. N Engl J Med. 2009. 361:680–689.

21. Oughton MT, Dascal A, Laporta D, Charest H, Afilalo M, Miller MA. Evidence of viremia in two cases of severe pandemic influenza A H1N1/09. Late-breaker poster session (V-1074i). Program and absctracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2009. San Francisco, CA. American Society for Microbiology.

22. Johnson KK, Faden H, Joshi P, Fasanello JF, Hernan LJ, Fuhrman BP, Welliver RC, Sharp JK, Schentag JJ. Two fatal pediatric cases of pandemic H1N1/09 influenza complicated by community-acquired methicillinresistant Staphylococcus aureus. Late-breaker poster session (G1-1558a). Program and abstracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2009. San Francisco, CA. American Society for Microbiology.

23. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus. Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, Hayden FG, Nguyen DH, de Jong MD, Naghdaliyev A, Peiris JS, Shindo N, Soeroso S, Uyeki TM. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med. 2008. 358:261–273.

24. Centers for Disease Control and Prevention (CDC). Intensive-care patients with severe novel influenza A (H1N1) virus infection - Michigan, June 2009. MMWR Morb Mortal Wkly Rep. 2009. 58:749–752.

25. Lee N, Chan PK, Hui DS, Rainer TH, Wong E, Choi KW, Lui GC, Wong BC, Wong RY, Lam WY, Chu IM, Lai RW, Cockram CS, Sung JJ. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis. 2009. 200:492–500.

26. Smee DF, Hurst BL, Wong MH, Bailey KW, Morrey JD. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob Agents Chemother. 2009. 53:2120–2128.

27. Nguyen JT, Hoopes JD, Smee DF, Prichard MN, Driebe EM, Engelthaler DM, Le MH, Keim PS, Spence RP, Went GT. Triple combination of oseltamivir, amantadine, and ribavirin displays synergistic activity against multiple influenza virus strains in vitro. Antimicrob Agents Chemother. 2009. 53:4115–4126.

28. Nguyen JT, Hoopers J, Smee D, Le M, Patick A, Dejong M, Went G, Faix D, Blair P, Prichard M. In vitro synergy of antiviral combinations against novel influenza A/H1N1 virus. Late-breaker slide session (V-537a. Program and absctracts of the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy. 2009. San Francisco, CA. American Society for Microbiology.

29. Kuiken T, Taubenberger JK. Pathology of human influenza revisited. Vaccine. 2008. 26:Suppl 4. D59–D66.

30. Centers for Disease Control and Prevention (CDC). Surveillance for pediatric deaths associated with 2009 pandemic influenza A (H1N1) virus infection-Unites States, April-August 2009. MMWR. 2009. 58:941–945.

31. Barlow GD. on behalf of the BSAC Council. Swine flu and antibiotics. J Antimicrob Chemother. 2009. 64:889–894.

32. Liem NT, Tung CV, Hien ND, Hien TT, Chau NQ, Long HT, Hien NT, Mai le Q, Taylor WR, Wertheim H, Farrar J, Khang DD, Horby P. Clinical features of human influenza A (H5N1) infection in Vietnam: 2004-2006. Clin Infect Dis. 2009. 48:1639–1646.

33. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006. 145:599–609.

34. Simmons CP, Bernasconi NL, Suguitan AL, Mills K, Ward JM, Chau NV, Hien TT, Sallusto F, Ha do Q, Farrar J, de Jong MD, Lanzavecchia A, Subbarao K. Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med. 2007. 4:e178.

35. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med. 2007. 357:1450–1451.

36. HK researchers propose harvesting convalescent plasma to fight new flu. cited 2009 Oct 21. Available from:URL: http://news.xinhuanet.com/english/2009-08/26/content_11948637.htm.

37. Department of Health & Human Services, Centers for Disease Control. Community Strategy for Pandemic Influenza Mitigation. cited 2009 Oct 21. Available from:URL: http://www.flu.gov/professional/community/commitigation.html.